Burke CM, Feinberg TY, Brosius S, Bhanot UK, Jain M, Linkov I, Siddiquee A, Guillan K, Ibanez G, Ndengu AA, Calder P, Rosales N, F Coutinho D, Long MM, Fishkin R, Thyparambil S, Glade Bender JL, Reed DR, You D, Ortiz MV, Slotkin EK, Kung AL, Dela Cruz FS. Anti-tumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expression. Mol Cancer Ther. 2025 Sep 5;. doi: 10.1158/1535-7163.MCT-25-0437. [Epub ahead of print] PubMed PMID: 40911899; PubMed Central PMCID: PMC12490493.
Dela Cruz FS, Stewart EA, Surdez D, Daley JD, Soragni A, Tomazou EM, Alvarez-Perez J, Feinberg TY, Amatruda JF, Ganapathi SS, Ohm JE, Heske CM, Cohen-Gogo S, Pesic D, Nash JO, Shlien A, Roundhill EA, Burchill SA, Crompton BD, Lawlor ER, Loeb DM, Delattre O, Mora J, Scotlandi K, Reed DR, Grohar PJ, Grünewald TGP, Kovar H, Bailey KM. Advancing preclinical biology for Ewing Sarcoma: an international effort. Mol Cancer Ther. 2025 Sep 5;. doi: 10.1158/1535-7163.MCT-25-0428. [Epub ahead of print] PubMed PMID: 40911901.
Slotkin EK, Mauguen A, Dela Cruz FS, Ortiz MV, Avutu V, Meyers PA, Wexler LH, O’Donohue TJ, Kinnaman MD, Kelly CM, D’Angelo SP, Keohan ML, Gounder MM, Thornton K, Nacev BA, Chi P, Rosenbaum E, Dickson M, Pachhal S, Somwar R, Ladanyi M, Robb C, Pandit-Taskar N, Hwang S, Price A, Behr G, Reed DR, Kentsis A, Kung AL, Bender JG, Tap WD. ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results. JCO Oncol Adv. 2025;2(1):e2400095. doi: 10.1200/OA-24-00095. eCollection 2025. PubMed PMID: 40330140; PubMed Central PMCID: PMC12052087.
Tosh C, Tec M, White JB, Quinn JF, Ibanez Sanchez G, Calder P, Kung AL, Dela Cruz FS, Tansey W. A Bayesian active learning platform for scalable combination drug screens. Nat Commun. 2025 Jan 2;16(1):156. doi: 10.1038/s41467-024-55287-7. PubMed PMID: 39746987; PubMed Central PMCID: PMC11696745.
Smith MA, Houghton PJ, Lock RB, Maris JM, Gorlick R, Kurmasheva RT, Li XN, Teicher BA, Chuang JH, Dela Cruz FS, Dyer MA, Kung AL, Lloyd MW, Mossé YP, Stearns TM, Stewart EA, Bult CJ, Erickson SW. Lessons learned from 20 years of preclinical testing in pediatric cancers. Pharmacol Ther. 2024 Dec;264:108742. doi: 10.1016/j.pharmthera.2024.108742. Epub 2024 Nov 5. Review. PubMed PMID: 39510293; PubMed Central PMCID: PMC12085791.
Metts JL, Aye JM, Crane JN, Oberoi S, Balis FM, Bhatia S, Bona K, Carleton B, Dasgupta R, Dela Cruz FS, Greenzang KA, Kaufman JL, Linardic CM, Parsons SK, Robertson-Tessi M, Rudzinski ER, Soragni A, Stewart E, Weigel BJ, Wolden SL, Weiss AR, Venkatramani R, Heske CM. Roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials. Cancer. 2024 Nov 15;130(22):3785-3796. doi: 10.1002/cncr.35457. Epub 2024 Jun 28. PubMed PMID: 38941509; PubMed Central PMCID: PMC11511643.
Reed DR, Tulpule A, Metts J, Trucco M, Robertson-Tessi M, O’Donohue TJ, Iglesias-Cardenas F, Isakoff MS, Mauguen A, Shukla N, Dela Cruz FS, Tap W, Kentsis A, Morris CD, Hameed M, Honeyman JN, Behr GG, Sulis ML, Ortiz MV, Slotkin E. Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials. J Clin Oncol. 2024 Sep 1;42(25):2955-2960. doi: 10.1200/JCO.23.02717. Epub 2024 Jun 6. PubMed PMID: 38843482; PubMed Central PMCID: PMC11534082.
Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Kuwahara Y, Somwar R, Ladanyi M, Qu R, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy. Cancer Discov. 2024 Jun 3;14(6):965-981. doi: 10.1158/2159-8290.CD-23-0110. PubMed PMID: 38315003; PubMed Central PMCID: PMC11147720.
Elkin R, Oh JH, Dela Cruz F, Norton L, Deasy JO, Kung AL, Tannenbaum AR. Dynamic network curvature analysis of gene expression reveals novel potential therapeutic targets in sarcoma. Sci Rep. 2024 Jan 4;14(1):488. doi: 10.1038/s41598-023-49930-4. PubMed PMID: 38177639; PubMed Central PMCID: PMC10766622.
Kinnaman MD, Zaccaria S, Makohon-Moore A, Arnold B, Levine MF, Gundem G, Arango Ossa JE, Glodzik D, Rodríguez-Sánchez MI, Bouvier N, Li S, Stockfisch E, Dunigan M, Cobbs C, Bhanot UK, You D, Mullen K, Melchor JP, Ortiz MV, O’Donohue TJ, Slotkin EK, Wexler LH, Dela Cruz FS, Hameed MR, Glade Bender JL, Tap WD, Meyers PA, Papaemmanuil E, Kung AL, Iacobuzio-Donahue CA. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma. Cancer Res. 2023 Nov 15;83(22):3796-3812. doi: 10.1158/0008-5472.CAN-23-0385. PubMed PMID: 37812025; PubMed Central PMCID: PMC10646480.
Mundi PS, Dela Cruz FS, Grunn A, Diolaiti D, Mauguen A, Rainey AR, Guillan K, Siddiquee A, You D, Realubit R, Karan C, Ortiz MV, Douglass EF, Accordino M, Mistretta S, Brogan F, Bruce JN, Caescu CI, Carvajal RD, Crew KD, Decastro G, Heaney M, Henick BS, Hershman DL, Hou JY, Iwamoto FM, Jurcic JG, Kiran RP, Kluger MD, Kreisl T, Lamanna N, Lassman AB, Lim EA, Manji GA, McKhann GM, McKiernan JM, Neugut AI, Olive KP, Rosenblat T, Schwartz GK, Shu CA, Sisti MB, Tergas A, Vattakalam RM, Welch M, Wenske S, Wright JD, Canoll P, Hibshoosh H, Kalinsky K, Aburi M, Sims PA, Alvarez MJ, Kung AL, Califano A. A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies. Cancer Discov. 2023 Jun 2;13(6):1386-1407. doi: 10.1158/2159-8290.CD-22-1020. PubMed PMID: 37061969; PubMed Central PMCID: PMC10239356.
Gundem G, Levine MF, Roberts SS, Cheung IY, Medina-Martínez JS, Feng Y, Arango-Ossa JE, Chadoutaud L, Rita M, Asimomitis G, Zhou J, You D, Bouvier N, Spitzer B, Solit DB, Dela Cruz F, LaQuaglia MP, Kushner BH, Modak S, Shukla N, Iacobuzio-Donahue CA, Kung AL, Cheung NV, Papaemmanuil E. Clonal evolution during metastatic spread in high-risk neuroblastoma. Nat Genet. 2023 Jun;55(6):1022-1033. doi: 10.1038/s41588-023-01395-x. Epub 2023 May 11. PubMed PMID: 37169874.
Coutinho DF, Mundi PS, Marks LJ, Burke C, Ortiz MV, Diolaiti D, Bird L, Vallance KL, Ibáñez G, You D, Long M, Rosales N, Grunn A, Ndengu A, Siddiquee A, Gaviria ES, Rainey AR, Fazlollahi L, Hosoi H, Califano A, Kung AL, Dela Cruz FS. Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. Med. 2022 Nov 11;3(11):774-791.e7. doi: 10.1016/j.medj.2022.09.002. Epub 2022 Oct 3. PubMed PMID: 36195086; PubMed Central PMCID: PMC9669237.
Dorado García H, Pusch F, Bei Y, von Stebut J, Ibáñez G, Guillan K, Imami K, Gürgen D, Rolff J, Helmsauer K, Meyer-Liesener S, Timme N, Bardinet V, Chamorro González R, MacArthur IC, Chen CY, Schulz J, Wengner AM, Furth C, Lala B, Eggert A, Seifert G, Hundsoerfer P, Kirchner M, Mertins P, Selbach M, Lissat A, Dubois F, Horst D, Schulte JH, Spuler S, You D, Dela Cruz F, Kung AL, Haase K, DiVirgilio M, Scheer M, Ortiz MV, Henssen AG. Therapeutic targeting of ATR in alveolar rhabdomyosarcoma. Nat Commun. 2022 Jul 25;13(1):4297. doi: 10.1038/s41467-022-32023-7. PubMed PMID: 35879366; PubMed Central PMCID: PMC9314382.
Nunes C, Depestel L, Mus L, Keller KM, Delhaye L, Louwagie A, Rishfi M, Whale A, Kara N, Andrews SR, Dela Cruz F, You D, Siddiquee A, Cologna CT, De Craemer S, Dolman E, Bartenhagen C, De Vloed F, Sanders E, Eggermont A, Bekaert SL, Van Loocke W, Bek JW, Dewyn G, Loontiens S, Van Isterdael G, Decaesteker B, Tilleman L, Van Nieuwerburgh F, Vermeirssen V, Van Neste C, Ghesquiere B, Goossens S, Eyckerman S, De Preter K, Fischer M, Houseley J, Molenaar J, De Wilde B, Roberts SS, Durinck K, Speleman F. RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. Sci Adv. 2022 Jul 15;8(28):eabn1382. doi: 10.1126/sciadv.abn1382. Epub 2022 Jul 13. PubMed PMID: 35857500; PubMed Central PMCID: PMC9278860.
Woods AD, Berlow NE, Ortiz MV, Dela Cruz F, Siddiquee A, Coutinho DF, Purohit R, Freier KET, Michalek JE, Lathara M, Matlock K, Srivivasa G, Royer-Pokora B, Veselska R, Kung AL, Keller C. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. Pediatr Blood Cancer. 2022 Feb;69(2):e29401. doi: 10.1002/pbc.29401. Epub 2021 Oct 24. PubMed PMID: 34693628.
Shukla N, Levine MF, Gundem G, Domenico D, Spitzer B, Bouvier N, Arango-Ossa JE, Glodzik D, Medina-Martínez JS, Bhanot U, Gutiérrez-Abril J, Zhou Y, Fiala E, Stockfisch E, Li S, Rodriguez-Sanchez MI, O’Donohue T, Cobbs C, Roehrl MHA, Benhamida J, Iglesias Cardenas F, Ortiz M, Kinnaman M, Roberts S, Ladanyi M, Modak S, Farouk-Sait S, Slotkin E, Karajannis MA, Dela Cruz F, Glade Bender J, Zehir A, Viale A, Walsh MF, Kung AL, Papaemmanuil E. Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. Nat Commun. 2022 May 18;13(1):2485. doi: 10.1038/s41467-022-30233-7. PMCID: PMC9117241.
O’Donohue TJ, Ibanez G, Ferreira Coutinho D, Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Long M, Roberts SS, Kung AL, Dela Cruz FS. Translational Strategies for Repotrectinib in Neuroblastoma. Mol Cancer Ther. 2021 Sep 4;. doi: 10.1158/1535-7163.MCT-21-0126. [Epub ahead of print]
Spitzer B, Dela Cruz FS, Ibanez Sanchez GD, Zhang Y, Xiao W, Benayed R, Markova A, Rodriguez-Sanchez MI, Bouvier N, Roshal M, Kung AL, Shukla N. ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML. Blood Adv. 2021 Apr 13;5(7):1899-1902. doi: 10.1182/bloodadvances.2020003699. PubMed Central PMCID: PMC8045514.
Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, Mauguen A, Gushterova I, Ding H, Spraggon L, Darnell R, Califano A, Ladanyi M, Papaemmanuil E, Kung AL, Hyman DM, Roberts SS. Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer. Cancer Discov. 2019 May;9(5):605-616. doi: 10.1158/2159-8290.CD-18-0953. Epub 2019 Mar 15. PubMed Central PMCID: PMC6497560.
Slotkin EK, Bowman AS, Levine MF, Dela Cruz F, Coutinho DF, Sanchez GI, Rosales N, Modak S, Tap WD, Gounder MM, Thornton KA, Bouvier N, You D, Gundem G, Gerstle JT, Heaton TE, LaQuaglia MP, Wexler LH, Meyers PA, Kung AL, Papaemmanuil E, Zehir A, Ladanyi M, Shukla N. Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. Mol Cancer Res. 2021 Jul;19(7):1146-1155. doi: 10.1158/1541-7786.MCR-20-0722. Epub 2021 Mar 22. PubMed Central PMCID: PMC8293793.
Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 2015, 15: 311-6.
Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Med 2000; 6: 1335-1340.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL*, Armstrong SA*. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20: 66-78. *Corresponding authors.
Diolaiti D, Dela Cruz FS, Gundem G, Bouvier N, Boulad M, Zhang Y, Chou AJ, Dunkel IJ, Sanghvi R, Shah M, Geiger H, Rahman S, Felice V, Wrzeszczynski KO, Darnell RB, Antonescu CR, French CA, Papaemmanuil E, Kung AL, Shukla N. A recurrent novel MGA-NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma. Cold Spring Harb Mol Case Stud. 2018 Dec;4(6). doi: 10.1101/mcs.a003194. Print 2018 Dec. PubMed Central PMCID: PMC6318763.
Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Glade Bender JL, Kung AL. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. doi: 10.1186/s13073-016-0366-0. PubMed Central PMCID: PMC5088685.
Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000471. doi: 10.1101/mcs.a000471. PubMed Central PMCID: PMC4850889.
Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Wood AW, Livingston DM. Small molecule blockade of transcriptional co-activation of the Hypoxia-Inducible Factor pathway. Cancer Cell 2004, 6: 33-43.
Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, Komissarova EV, Hagan EA, Bodei L, Clemons PA, Dela Cruz FS, Dhall D, Diolaiti D, Fraker DA, Ghavami A, Kaemmerer D, Karan C, Kidd M, Kim KM, Kim HC, Kunju LP, Langel Ü, Li Z, Lee J, Li H, LiVolsi V, Pfragner R, Rainey AR, Realubit RB, Remotti H, Regberg J, Roses R, Rustgi A, Sepulveda AR, Serra S, Shi C, Yuan X, Barberis M, Bergamaschi R, Chinnaiyan AM, Detre T, Ezzat S, Frilling A, Hommann M, Jaeger D, Kim MK, Knudsen BS, Kung AL, Leahy E, Metz DC, Milsom JW, Park YS, Reidy-Lagunes D, Schreiber S, Washington K, Wiedenmann B, Modlin I, Califano A. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018 Jul;50(7):979-989. doi: 10.1038/s41588-018-0138-4. Epub 2018 Jun 18. PubMed Central PMCID: PMC6421579.
Adane B, Alexe G, Seong BKA, Lu D, Hwang EE, Hnisz D, Lareau CA, Ross L, Lin S, Dela Cruz FS, Richardson M, Weintraub AS, Wang S, Iniguez AB, Dharia NV, Conway AS, Robichaud AL, Tanenbaum B, Krill-Burger JM, Vazquez F, Schenone M, Berman JN, Kung AL, Carr SA, Aryee MJ, Young RA, Crompton BD, Stegmaier K. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. Cancer Cell. 2021 Jun 14;39(6):827-844.e10. doi: 10.1016/j.ccell.2021.05.007. PubMed Central PMCID: PMC8378827.
Hahn WC, Bader JS, Braun TP, Califano A, Clemons PA, Druker BJ, Ewald AJ, Fu H, Jagu S, Kemp CJ, Kim W, Kuo CJ, McManus M, B Mills G, Mo X, Sahni N, Schreiber SL, Talamas JA, Tamayo P, Tyner JW, Wagner BK, Weiss WA, Gerhard DS. An expanded universe of cancer targets. Cell. 2021 Mar 4;184(5):1142-1155. doi: 10.1016/j.cell.2021.02.020. Review. PubMed Central PMCID: PMC8066437.
Henssen AG, Reed C, Jiang E, Garcia HD, von Stebut J, MacArthur IC, Hundsdoerfer P, Kim JH, de Stanchina E, Kuwahara Y, Hosoi H, Ganem NJ, Dela Cruz F, Kung AL, Schulte JH, Petrini JH, Kentsis A. Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. Sci Transl Med. 2017 Nov 1;9(414). doi: 10.1126/scitranslmed.aam9078. PubMed Central PMCID: PMC5683417.
Chen Y, Cruz FD, Sandhu R, Kung AL, Mundi P, Deasy JO, Tannenbaum A. Pediatric Sarcoma Data Forms a Unique Cluster Measured via the Earth Mover’s Distance. Sci Rep. 2017 Aug 1;7(1):7035. doi: 10.1038/s41598-017-07551-8. PubMed Central PMCID: PMC5539155.
Church AJ, Calicchio ML, Nardi V, Skalova A, Pinto A, Dillon DA, Gomez-Fernandez CR, Manoj N, Haimes JD, Stahl JA, Dela Cruz FS, Tannenbaum-Dvir S, Glade-Bender JL, Kung AL, DuBois SG, Kozakewich HP, Janeway KA, Perez-Atayde AR, Harris MH. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018 Mar;31(3):463-473. doi: 10.1038/modpathol.2017.127. Epub 2017 Nov 3.
Giulino-Roth L, van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, Bolaender A, Erdjument-Bromage H, Sadek J, Chadburn A, Barth MJ, Dela Cruz FS, Rainey A, Kung AL, Chiosis G, Cesarman E. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Mol Cancer Ther. 2017 Sep;16(9):1779-1790. doi: 10.1158/1535-7163.MCT-16-0848. Epub 2017 Jun 15. PubMed Central PMCID: PMC5587381.
Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med. 2016 Dec 23;8(1):133. doi: 10.1186/s13073-016-0389-6. PubMed Central PMCID: PMC5180407.
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Hofmann F, Garcia-Echeverria C, Pearson MA, Anderson KC, Kung AL. Inhibition of the Insulin-Like Growth Factor Receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors. Cancer Cell 2004, 5: 221-230.
Ziegler DS, Wright RD, Kesari S, Lemieux M, Tran MA, Jain M, Zawel L, Kung AL. Blockade of the Inhibitor of Apoptosis Proteins overcomes resistance to growth factor inhibitors in glioblastoma multiforme. J Clin Invest 2008, 188: 3109-3122.
Green AL, Ramkissoon SH, McCauley D, Jones K, Perry JA, Hsu JH, Ramkissoon LA, Maire CL, Hubbell-Engler B, Knoff DS, Shacham S, Ligon KL, Kung AL. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro Oncol 2015, 17: 697-707.
Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL*, Engelman JA*, Wong KK*. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483: 613-617. *Corresponding authors
Herter-Sprie GS, Kung AL, Wong KK. New cast for a new era: preclinical cancer drug development revisited. J Clin Invest 2013, 123: 3639-3645.
O’Neill AF, Dearling JL, Wang Y, Tupper T, Sun Y, Aster JC, Calicchio ML, Perez-Atayde AR, Packard AB, Kung AL. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. Clin Cancer Res 2014, 20: 678-687.
Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha A, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
Xia X, Lemieux M, Li W, Carroll JS, Brown M, Liu XS, Kung AL. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 2009, 106: 4260-4265.
Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE. Selective inhibition of BET bromodomains. Nature 2010, 468: 1067-1073.
Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright R, Wagner G, Verdine GL, Korsmeyer SJ. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004, 305: 1466-1470.
Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE. Direct inhibition of the Notch transcription factor complex. Nature 2009, 462: 182-188.
Chen C, Wonsey DR, Lemieux ME, Kung AL. Differential disruption of EWS-FLI1 binding by DNA-binding agents. PLoS One 2013, 8: e69714.